ECI
SRPT icon

EFG Capital International’s Sarepta Therapeutics SRPT Stock Holding History

EFG Capital International’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$231K Buy
+2,020
New +$260K 0.05% 136

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

EFG Capital International's SRPT Position: Q2 2023 in Review

EFG Capital International opened a new position in Sarepta Therapeutics (SRPT) in Q2 2023: 2,020 shares worth $231K. The stake represents 0.05% of the portfolio and ranks #136 among its holdings.

405 funds tracked by Wall St. Rank hold SRPT as of Q2 2023.

  • EFG Capital International held 2,020 shares of Sarepta Therapeutics worth $231K as of Q2 2023.
  • Sarepta Therapeutics was a new EFG Capital International position in Q2 2023.
  • Sarepta Therapeutics made up 0.05% of EFG Capital International's portfolio in Q2 2023, its #136 holding.
  • 405 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.